Founder Securities(SH:601901) Zheng Quan Zhi Xing·2025-09-01 09:20Core Viewpoint - The report outlines the continuous supervision and compliance of Shanghai Sailun Biotechnology Co., Ltd. by the sponsor, Founder Securities, during the first half of 2025, ensuring adherence to relevant regulations and monitoring the company's operations and governance [1][2][3]. Continuous Supervision Work - The sponsor has established a comprehensive supervision system and executed a work plan to monitor the company effectively [2]. - A continuous supervision agreement was signed between the sponsor and Sailun Biotechnology, clarifying rights and obligations during the supervision period [2]. - The sponsor conducted regular communication, site visits, and due diligence to understand the company's operational status [2][3]. Compliance and Governance - The sponsor ensured that the company and its management adhered to laws, regulations, and business rules set by the Shanghai Stock Exchange [2][3]. - The company was guided to establish effective internal control systems, including financial management and accounting practices [3]. Financial Performance - For the first half of 2025, the company reported a revenue of approximately 100.82 million yuan, a 2.82% increase from the previous year [6]. - The net profit attributable to shareholders was approximately 32.98 million yuan, reflecting a 2.07% increase year-on-year [6]. - The company's total assets reached approximately 1.14 billion yuan, a 1.38% increase compared to the end of the previous year [6]. Core Competitiveness - The company has developed proprietary technologies in the field of antivenom and antitoxin products, establishing a strong competitive edge in research and production [10][11]. - The company’s main products, including snake antivenom and tetanus immunoglobulin, are unique in the domestic market, with ongoing improvements in production processes [10][11]. Research and Development - The company’s R&D expenditure accounted for 8.41% of its revenue, a decrease of 4.23 percentage points compared to the previous year [15]. - New product development projects include broad-spectrum snake antivenom and recombinant snake venom coagulase, which are in various stages of research [16][17]. Fund Utilization - The company raised approximately 89.38 million yuan from its initial public offering, with net proceeds of about 78.49 million yuan after deducting issuance costs [18]. - As of June 30, 2025, the company had utilized approximately 283.69 million yuan of the raised funds, with a remaining balance of approximately 559.85 million yuan [18][20]. Shareholding Structure - As of June 30, 2025, there were no shareholding reductions, pledges, or freezes among the company's major shareholders and management [20].